Scott Evans

Professor Evans research interests include the design, monitoring, analyses, and reporting of and education in clinical trials and diagnostic studies. As a thought leader in clinical research methodologies, Professor Evans emphasizes the importance of depth of understanding the research questions, with a focus on pragmatic and patient-centric benefit:risk assessment. Professor Evans works closely with his friend and colleague, Professor Toshi Hamasaki, leading a team of researchers and students to advance clinical trial and diagnostic study science.

Professor Evans is the: Director of the Statistical and Data Management Center for the Antibacterial Resistance Leadership Group (ARLG) funded by NIAID/NIH; the co-PI of the Coordinating Center for the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium funded by the NCI/NIH, the co-PI of the Data Coordinating Center of the Clamp OR Delay among neonates with Congenital Heart Disease (CORD-CHD) clinical trial funded by the NHLBI/NIH; and the PI of the statistical center for the Combat Trauma Infection Prevention and Management Wartime Preparedness (COMBAT TRAUMA) funded by the Henry Jackson Foundation. He has published more than 250 peer-reviewed manuscripts and four books on clinical trials.

Professor Evans has created many impactful methodologies including DOOR, BED-FRAME / AWA, SMART COMPASS, MASTERMIND, ITD, DOOR MAT, and PIPs.

The desirability of outcome ranking (DOOR) is a patient-centric paradigm for the design, data monitoring, analysis, interpretation, and reporting of clinical trials and other research studies based on benefit-risk evaluation. The DOOR uses outcomes to analyze patients rather than patients to analyze outcomes by comparing the experiences of trial participants in different treatment arms by the desirability of the overall patient outcome. DOOR has been utilized in several studies including studies that have provided the basis for treatment guidelines for vancomycin dosing for MRSA, and provided the basis for treatment guidelines to use ceftazidime-avibactam instead of colistin for infections due to Carbapenem-Resistant Enterobacteriaceae. The ALRG is using DOOR in the Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized with Pseudomonas aeruginosa (PHAGE), Dalbavancin as an Option for Treatment of S. aureus bacteremia (DOTS), and Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia (FAST) clinical trials. The FDA has implemented two DOOR Fellowships through ORISE. DOOR has been recommended and applied to data and safety monitoring board (DSMB) evaluations. Guidance from the Council for International Organizations of Medical Sciences recommends DOOR for benefit-risk evaluation in a report “Benefit-Risk Balance for Medicinal Products”. The SDMC developed a statistical analysis plan (SAP) for DOOR and offers a free online application (https://methods.bsc.gwu.edu/) for researchers implementing DOOR analyses or designing studies utilizing the DOOR paradigm.

Benefit-Risk Evaluation of Diagnostics: A Framework (BED-FRAME) and Average Weighted Accuracy (AWA) provides a systematic and pragmatic approach to evaluate and compare diagnostic alternatives to aid in clinical decision-making based on diagnostic yield i.e., the distribution of true positives, true negatives, false positives, and false negatives. The value of the yield depends on the relative importance of false positive vs. false negative errors as different errors carry different consequences. However, prevalence and relative importance vary geographically and temporally. BED-FRAME and AWA were applied to design the RADICAL study that evaluated the utility of a host response–based diagnostic test in categorizing acute respiratory tract illness into bacterial, viral, or neither etiology, and to evaluate rapid molecular diagnostics for detecting resistance associated with carbapenem-resistant (CR) Enterobacterales, CR P. aeruginosa, and CR A. baumannii. A freely-available online tool for BED-FRAME analyses is available: https://extapps.bsc.gwu.edu/shinypub/arlg/BED_FRAME/.

Sequential, Multiple-Assignment, Randomized Trials for Comparing Personalized Antibiotic Strategies (SMART COMPASS) is a trial design that compares strategies for antibiotic decision-making. The strategies allow for therapeutic adjustment if resistance or intolerability is observed acknowledging that patient management is a dynamic sequence of decisions e.g., empiric and definitive therapy, with therapeutic adjustments made over time. Adjustments are tailored to the unique circumstances encountered with individual patients as new information e.g., AST results, becomes available. This pragmatic design mirrors clinical antibiotic treatment decision-making and identifies the patient management strategy that optimizes outcomes.

The Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) was developed to evaluate multiple diagnostics simultaneously within a single study, providing efficiencies of specimen collection and characterization. MASTERMIND offers central trial organization, standardization of methods and definitions, and common reference standards.

MASTERMIND was utilized to evaluate simultaneously the performance of nucleic acid amplification tests for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis in extragenital sites. The study resulted in FDA clearance of the first two diagnostic tests for extragenital testing for these pathogens.

Intention-to-diagnose (ITD) in diagnostic studies is the analog to intention-to-treat (ITT) in clinical trials. Distinct research foci: pragmatic application accuracy, pragmatic scientific accuracy, and explanatory scientific accuracy are defined. Selection of appropriate analysis sets and the handling of invalid and indeterminate results depend on the specific focus. Application of ITD carries similar protections for diagnostic studies, i.e., valid statistical inference e.g., error control during hypothesis testing and correct coverage probabilities for confidence interval estimates of sensitivity or specificity, and well-defined populations from which to estimate parameters and to generalize results. In parallel to ITT analyses for clinical trials, ITD analyses provides the most realistic and unbiased answer to the most relevant question for diagnostic tests – that is, how do they perform in clinical practice, by fully capturing the range of consequences associated with test implementation in the intended-use setting, in lieu of a clinical outcome study. A freely-available online tool for ITD analyses is available:  https://extapps.bsc.gwu.edu/shinypub/arlg/ITD-standard-edition/.

The Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) is a framework for assessing and comparing antibiotic selection strategies in the presence of drug resistance. It is desirable to select an antibiotic from the narrowest spectrum for which the target infection is susceptible. This minimizes toxicity, cost, and the development of resistance due to selective pressure.

Clinical trials are often monitored for efficacy or futility. Several methods for interim monitoring of CTs have been developed. Although informative, few of these methods convey information regarding effect sizes, or use prediction to convey information regarding potential effect size estimates and associated precision, with trial continuation. Professor Evans developed “predicted intervals” (PIs) and predicted interval plots (PIPs) as a flexible and practical tool for quantitative monitoring of clinical trials. PIs provide information regarding effect sizes, are invariant to study design and endpoint scale, and provide flexibility in the decision-making process. PIs provide a valuable tool for Data Monitoring Committees.

Professor Evans delivered numerous invited keynote plenary addresses about his research at professional meetings including the: ASA Biopharmaceutical Section Regulatory Industry Workshop (2017 and 2020), Deming Conference on Applied Statistics (2018 and 2025), International Chinese Statistical Association Applied Statistics Symposium (2021), FDA/AdvaMed Medical Device Statistical Issues Conference (2022), Japanese Biometric Society (2009), Midwest Biopharmaceutical Statistics Workshop (2009), UMBC Probability and Statistics Day (2023), Interfarma and ANVISAs’ Multidisciplinary Symposium on Noninferiority Trials (2010), Statistics in Pharmaceutical Conference (2023), Infectious Disease Clinical Research Program (IDCRP) Science Symposium (2025), Japan Society of Clinical Trials and Research (2025), Joint Graybill / WNAR / IMS Conference (2024), Harvard Catalyst Biostatistics Symposium (2024), and the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation, IMARI (planned 2027).

Interviews of Professor Evans and his work can be found here:

1. Internationally Recognized Leader in Clinical Trials, Biostatistics, and Infectious Disease Research Joins the George Washington University.  https://publichealth.gwu.edu/content/internationally-recognized-leader-clinical-trials-biostatistics-and-infectious-disease. 2018.
2. How can Novel Statistical Methods Tackle Antibiotic Resistance? Interview with Scott Evans. Cytel Blog. http://www.cytel.com/blog/novel-statistics-antibiotic-resistance-scott-evans. 2017.
3. Q&A with Scott Evans, CHANCE Executive Editor. American Statistical Association. http://www.amstat.org/ASA/Publications/Q-and-As/Scott-Evans.aspx.
4. Outsmarting Superbugs. Plymouth Magazine. https://www.plymouth.edu/magazine/alumni-green/outsmarting-superbugs/. 2016.
5. Superbugs: An Epidemic Begins. Harvard Magazine. http://harvardmagazine.com/2014/05/superbug. 2014.
6. Stats + Stories on NPR: Superbug Statistics. https://statsandstories.net/health1/superbug-statistics. 2019.
7. Stats + Stories on NPR: Sports Statistics. https://soundcloud.com/statsandstories/sports-stats-in-2019/s-Fidnl. 2019.
    

Sites of Note

Professor Evans’ talk on the history and impact of The Biostatistics Center’s studies and methodological research, the Center’s illustrious faculty and researchers, the education of students, and the career development of researchers: https://biostatcenter.gwu.edu/50anniversary_address

Desirability Of Outcome Ranking (DOOR): https://methods.bsc.gwu.edu/  

Benefit-risk Evaluation for Diagnostics: A FRAMEwork (BED-FRAME):   https://extapps.bsc.gwu.edu/shinypub/arlg/BED_FRAME/ 

Intention-to-Diagnose (ITD): https://extapps.bsc.gwu.edu/shinypub/arlg/ITD-standard-edition/

Books

Fundamental Concepts for New Clinical Trialists
Sample Size Determination in Clinical Trials with Multiple Endpoints
Group-Sequential Clinical Trials with Multiple Co-Objectives 
Benefit-risk Balance for Medicinal Products 

1. Evans SR, Pennello G, Zhang S, Li Y, Wang Y, Cao Q, Komarow L, Hamasaki T, Petrides V, Meier K, Galicia NP, Fowler VG Jr, Boucher HW, Doernberg SB, Banerjee R, Rigatto MH, Kreiswirth BN, Bonomo RA, Chambers HF, Patel R. Intention-to-diagnose and distinct research foci in diagnostic accuracy studies. Lancet Infect Dis. 2025 Aug;25(8):e472-e481. doi: 10.1016/S1473-3099(25)00070-2. Epub 2025 Mar 27. PMID: 40158520.
2. Evans SR, Wu Q, Hamasaki T. Patient-Centric Pragmatic Clinical Trials: Opening the DOOR. Stat Med. 2026 Feb;45(3-5):e70328. doi: 10.1002/sim.70328. PMID: 41677577.
3. Hamasaki T, He Y, Wu Q, Howard-Anderson J, Boucher HW, Doernberg SB, Holland TL, Powers JH 3rd, Wang J, Diao G, van Duin D, Fowler VG Jr, Chambers HF, Evans SR. A patient-centric paradigm and tool for clinical research: the DOOR is open. Antimicrob Agents Chemother. 2025 Nov 24:e0147825. doi: 10.1128/aac.01478-25. Epub ahead of print. PMID: 41277847.
4. Evans SR, Fleming TR, Janes H, Dodd LE. Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards. JAMA. Published online March 23, 2026. doi:10.1001/jama.2026.4175.
5. Ge L, Hamasaki T, Evans SR. Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies. Ther Innov Regul Sci. 2025 Mar;59(2):234-244. doi: 10.1007/s43441-024-00720-8. Epub 2024 Dec 17. PMID: 39688768.
6. Zeng L, Hamasaki T, Evans SR. Data Monitoring Committee Reports: Telling the Data's Story. Ther Innov Regul Sci. 2025 Mar;59(2):222-233. doi: 10.1007/s43441-024-00727-1. Epub 2024 Dec 10. PMID: 39656431.
7. Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler Jr VG, Bouhcer HW. The future ain’t what it used to be…out with the old…in with the better: Antibacterial Resistance Leadership Group (ARLG) innovations. Clin Infect Dis 2023; 77:321–30.
8. Evans SR. Zeng L, Dai W. The DSMB: The Toughest Job in Clinical Trials. Published January 24, 2023. NEJM Evid 2023; 2 (2). DOI: https://doi.org/10.1056/EVIDctw2200220.
9. Evans SR, Hamasaki T. Weighing Evidence: Robustness vs. Quantity. JNCI: Journal of the National Cancer Institute, 115(1), 1–3. https://doi.org/10.1093/jnci/djac186. 2023.
10. Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clin Infect Dis 2023;77(S4):S279–87.
11. Evans SR. Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards. NEJM Evid 2022; 1 (1). DOI: 10.1056/EVIDctw2100005
12. Evans SR. Radical Thinking: Scientific Rigor and Pragmatism. Statistics in Biopharmaceutical Research, 14:2, 140-152, 2022. https://doi.org/10.1080/19466315.2022.2026460.
13. Evans SR. Our Most Important Discovery: The Question. Statistics in Biopharmaceutical Research, 14:4, 398-407, 2022. https://doi.org/10.1080/19466315.2021.1972833.
14. Evans SR. Paraoan D, Perlmutter J, Raman SR, Sheehan JJ, Hallinan ZP. Real‑World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-020-00248-7. 2021. May;55(3):545-552.
15. Evans SR. Waking up to p: Comment on “The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations”, Statistics in Biopharmaceutical Research, 13:1, 19-21, DOI: 10.1080/19466315.2020.1811151. 2021.
16. Benjamini Y, De Veaux RD, Efron B, Evans S, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President’s Task Force Statement on Statistical Significance and Replicability. The Annals of Applied Statistics. Vol. 15, No. 3, 1084–1085. https://doi.org/10.1214/21-AOAS1501. © Institute of Mathematical Statistics, 2021.
17. Hamasaki T, Hung HMJ, Hsiao, CF, Evans SR. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2020.106244. 2021.
18. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y. Ticagrelor and Aspirin versus Aspirin in Acute Ischemic Stroke or TIA. N Engl J Medicine. 2020.
19. Evans SR, Knutsson M, Amarenco P, Albers GW, Bath PN, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC. Methodologies for pragmatic and efficient assessment of benefits and harms: application to the SOCRATES trial. Clinical Trials, Vol. 17(6) 617–626, 2020.
20. Evans SR, Bigelow R, Chuang-Stein C, Ellenberg S, Gallo P, He W, Jiang Q, Rockhold F. Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. Annals of Internal Medicine. 2020.
21. Liu Y, Tsalik EL, Jiang Y, Ko ER, Woods CW, Henao R, Evans SR. Average Weighted Accuracy (AWA): Pragmatic Analysis for a RADICAL Study. Clin Infect Dis.; 2020.
22. Evans SR, DeGruttola V. Innovations in Design, Education, and Analysis (IDEA) Introduction. Clin Infect Dis.; 2019;68(11):1960.
23. Jiang Y, Follmann D, Evans SR. Superbug Clinical Trials. Wiley StatsRef-Statistics Reference Online. 2019.
24. Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JL, Tran TTT, Harris AD, Fowler, Jr. VG, Boucher H, Kreiswirth BN, Bonomo RA, van Duin D, Paterson DL, Chambers H. Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). Clin Infect Dis. 2019;68(11):1961–7. PMID: 30351426 PMC Journal - In Process
25. Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler Jr VG, Chambers HF, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG). Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2019;68(11):1961–7. PMID: 30351426 PMC Journal - In Process
26. Evans, SR, Rubin DB, Powers JH, Follmann D. Analysis Populations in Anti-infective Clinical Trials: Whom to Analyze? Stat Commun Infect Dis. 2018; NIHMSID 988165
27. Hamasaki T, Evans SR, Asakura K. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: a review. J Biopharm Stat. 2018; 28(1):28-51. PMID: 29083951 PMCID: PMC6135538
28. Huskins WC, Fowler Jr VG, Evans SR. Adaptive Designs for Clinical Trials:  Application to Healthcare Epidemiology Research. Clin Infect Dis. 2018; 66(7):1140-46. PMID: 29121202 PMCID: PMC6018921
29. Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler Jr VG, Paterson DL, Bonomo RA, Evans SR. Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018; 66(2):163-171. PMID: 29020404 PMCID: PMC5850032
30. Evans SR, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls? Stat Commun Infect Dis. 2017; 9(1): 20160003. PMID: 28757914 PMCID: PMC5529043
31. Patel R, Tsalik EL, Petzold E, Fowler Jr. VG, Klausner JD, Evans SR. Antibacterial Resistance Leadership Group (ARLG). MASTERMIND: Bringing Microbial Diagnostics to the Clinic. Clin Infect Dis. 2017; 64(3):355-360. PMID: 27927867 PMCID: PMC5894935
32. Huvane J, Komarow L, Hill C, Tran TT, Pereira C, Rosenkranz S, Finnemeyer M, Earley M, Jiang HJ, Wang R, Lok J, Evans SR; Statistical and Data Management Center of the Antibacterial Resistance Leadership Group (ARLG). Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64(suppl_1):S18-S23. PMID: 28350899 PMCID: PMC5848245
33. Evans SR, Harris AD. Methods and issues in studies of CRE. Virulence. 2017; 8(4):453-459. PMID: 27470534 PMCID: PMC5477696
34. Asakura K, Hamasaki T, Evans SR. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints. Biom J. 2017; 59(4):703-731. PMID: 27757980 PMCID: PMC6222168
35. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler Jr VG, Chambers HF, Bonomo RA. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol. 2016; 55(1):134-144. PMID: 27795336 PMCID: PMC5228224
36. Evans SR, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation. Stat Biopharm Res. 2016; 8(4):386-393. PMID: 28435515 PMCID: PMC5394932
37. Evans SR, Pennello G, Pantoja-Galicia N, Jiang H, Hujer AM, Hujer KM, Manca C, Hill C, Jacobs MR, Chen L, Patel R, Kreiswirth BN, Bonomo RA. Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). Clin Infect Dis. 2016; 63(6):812-7. PMID: 27193750 PMCID: PMC4996133
38. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong L; SOCRATES Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Medicine. 2016; 375(1):35-43. PMID: 27160892
39. Pennello G, Pantoja-Galicia N, Evans SR. Comparing diagnostic tests on benefit-risk. J Biopharm Stat. 2016; 26(6):1083-1097. PMID: 27548805 PMCID: PMC5471848
40. Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler Jr. VG, Chambers HF, Kreiswirth BN, and Bonomo RA;  Antibacterial Resistance Leadership Group. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2016; 62(2):181-9. PMID: 26409063 PMCID: PMC4690483
41. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D,  Chuang-Stein C, Cosgrove SE, Fowler Jr. VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015; 61(5):800-6. PMID: 26113652 PMCID: PMC4542892
42. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies. Ann Intern Med. 2015; 163:127-134. PMID: 26054047 PMCID: PMC4510023.
43. Evans SR, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB. Peripheral Neuropathy in HIV: Prevalence and Risk Factors. AIDS. 2011; 25(7):919-28. PMID: 21330902 PMCID: PMC3196556
44. Evans SR. Fundamentals of Clinical Trial Design. J Exp Stroke Transl Med. 2010; 3(1):19-27. PMID: 21533012 PMCID: PMC3083073
45. Evans SR. Clinical Trial Structures. J Exp Stroke Transl Med. 2010; 3(1):8-18. PMID: 21423788 PMCID: PMC3059315
46. Evans SR. Common Statistical Concerns in Clinical Trials. J Exp Stroke Transl Med. 2010; 3(1):1-7. PMID: 21423790 PMCID: PMC3059317
47. Evans SR. Estudos Clinicos de Nao-Inferioridade. Revista Brasileira de Medicina. 2010; 3(1):1-7.
48. Evans SR, Li L, Wei LJ. Data Monitoring in Clinical Trials Using Prediction. Drug Inf J. 2007; 41(6):733-742.
49. Evans SR, Fichtenbaum CJ, Aberg JA; A5087 Study Team. Comparison of Direct and Indirect Measurement of LDL-C in HIV Infected Individuals: ACTG 5087. HIV Clin Trials. 2007; 8(1):45-52. PMID: 17434848 PMCID: PMC2288650
50. Evans SR. When and How Can Endpoints Be Changed After Initiation of a Randomized Clinical Trial? PLoS Clin Trials. 2007; 2(4):e18. PMID: 17443237 PMCID: PMC1852589
51. Evans SR, Simpson DM, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC; Neurologic AIDS Research Consortium; AIDS Clinical Trials Group. A Randomized Trial Evaluating Prosaptide™ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS One. 2007; 2(6):e551. PMID: 17653259 PMCID: PMC1919427
52. Evans SR, Wang R, Yeh TM, J Anderson, Haija R, McBratney-Owen PM, Peeples L,  Sinha S, Xanthakis V, Rajicic N, Zhang J. Evaluation of Distance Learning in an Introduction to Biostatistics Course. Statistical Education Research Journal. 2007; 6(2):59-77.
53. Evans SR, Li L. A Comparison of Goodness of Fit Tests for the Logistic GEE Model. Stat Med. 2005; 24(8):1245-61. PMID: 15580592
54. Evans SR, Hosmer DW. Goodness of Fit Tests for Mixed Effects Logistic Models Characterized by Clustering. Commun Stat Theory Methods. 2004; 33(5):1139-1155.
55. Evans SR, Hosmer DW. Goodness of Fit Tests for Logistic GEE Models: Simulation Results. Commun Stat Simul Comput. 2004; 33(1):247-258.
56. Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. A Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An ACTG Clinical Study. J Clin Oncol. 2002; 20(15):3236-41. PMID: 12149296 

• PUBH 6866: Principles of Clinical Trials
• PUBH 8888: Advanced Topics in Clinical Trials

Professor Evans served as the President of the Society for Clinical Trials (SCT) and as the Chair of the Trial of the Year Committee for the SCT.

Professor Evans has served on more than 100 DSMBs for government, industry, and academic-sponsored clinical trials. He was the Editor of a Statistical Mini-Series "Independent Oversight of Clinical Trials: Protecting Patients and Scientific Integrity" for the New England Journal of Medicine (NEJM) Evidence.

Dr. Evans served on an FDA Advisory Committee.

Professor Evans served as the co-Chair of the Benefit-Risk Balance for Medicinal Products Working Group of the Council for International Organizations of Medical Sciences (CIOMS).

Professor Evans served as the Editor-in-Chief of CHANCE, Co-Editor of a Special Section of Clinical Infectious Diseases (CID) entitled Innovations in Design, Education, and Analysis (IDEA), an Advisory Editor for Statistics in Biopharmaceutical Research, and the Editor-in-Chief of Statistical Communications in Infectious Diseases (SCID).

Professor Evans served as the President of the Boston Chapter of the American Statistical Association (ASA), Chair of the Development Committee of ASA, Chair of the Teaching Statistics in the Health Sciences section of ASA, Chair of the Medical Devices and Diagnostics section of the ASA, and the Chair of the Statistics in Sports section of ASA. Professor Evans served as a member of the ASA’s Presidential Task Force on p-values and statistical significance.

Professor Evans has served on the Board of Directors for the SCT, ASA, Mu Sigma Rho (the National Honorary Society for Statistics), Frontier Science Foundation, and the Accelerating Anticancer Agent Development and Validation (AAADV).

Professor Evans served as a member of the Steering Committee of the Clinical Trials Transformation Initiative (CTTI), and the Executive Committee for the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, and Networks (ACTTION).

Professor Evans is the Co-founder of the biennial New England Symposium on Statistics in Sports (NESSIS).